Last updated: 08/30/2024 18:10:42
Crossover Study to assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors
Trial description: This is a three stage, open label, randomized-sequence, single-crossover Phase 1 study to evaluate the relative bioavailability (BA) and Bioequivalence (BE) of niraparib administered as a tablet formulation compared to the reference capsule formulation currently marketed in the United States. Stage 3 evaluates the effect of a high-fat meal on niraparib pharmacokinetics (PK) following a single dose of the tablet. The Extension Phase of this study is to enable participants enrolled in the study to continue to receive treatment with niraparib tablets if they are tolerating it and, in the Investigator’s opinion, may receive benefit.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC[0-t]) for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0 to inf]) for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Maximum observed plasma concentration (Cmax) for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Time to reach maximum observed plasma concentration (Tmax) for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Terminal elimination half-life (T1/2) for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Apparent total body clearance for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Apparent terminal volume of distribution for niraparib-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 168 hours post-dose
Time from administration of the dose to the first quantifiable concentration (Tlag) for niraparib-Stage 3 PK Phase
Timeframe: Up to 168 hours post-dose
Secondary outcomes:
Number of participants with treatment emergent adverse events (TEAEs), serious TEAEs and discontinuations due to TEAEs-Stages 1, 2 and 3 PK Phase
Timeframe: Up to 54 days
Number of participants with TEAEs, serious TEAEs and discontinuations due to TEAEs-Extension Phase
Timeframe: Approximately 1 year
Interventions:
Drug: Niraparib Tablet
Drug: Niraparib Capsule
Enrollment:
236
Observational study model:
Not applicable
Primary completion date:
2022-30-12
Time perspective:
Not applicable
Clinical publications:
Falchook G, Patnaik A, Richardson D, Harvey R, Sharma M, Hafez N, et al. . A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther.
DOI: 10.1016/j.clinthera.2024.01.004
PMID: 38423866
Medical condition
Neoplasms
Product
Not applicable
Collaborators
Not applicable
Study date(s)
December 2017 to June 2023
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- PK Phase: To be considered eligible to participate in this study, all of the following requirements must be met:
- Participants with histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors that have failed to respond to standard therapy, has progressed despite standard therapy, or for which no standard therapy exists, and who may benefit from treatment with a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor as assessed by the Investigator.
- PK Phase:
- Known diagnosis of immunodeficiency
Inclusion and exclusion criteria
Inclusion criteria:
- PK Phase: To be considered eligible to participate in this study, all of the following requirements must be met:
- Participants with histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors that have failed to respond to standard therapy, has progressed despite standard therapy, or for which no standard therapy exists, and who may benefit from treatment with a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor as assessed by the Investigator.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Adequate organ function as defined: Absolute neutrophil count ≥ 1,500 per microliter (/μL) (For Stage 3: >=1000/μL); Platelets ≥ 100,000/μL; Hemoglobin ≥ 9 grams per deciliter (g/dL) (5.6 millimolar [mM]); Serum creatinine ≤ 1.5 × the upper limit of normal (ULN) or a calculated creatinine clearance ≥ 60 milliliters per minute (mL/min) using the Cockcroft-Gault equation or 24-hour urine creatinine clearance.; Total bilirubin ≤ 1.5 × ULN except in participants with Gilbert’s syndrome. Participants with Gilbert’s syndrome may enroll if direct bilirubin ≤ 1.5 × ULN of the direct bilirubin; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN unless liver metastases are present, in which case, they must be ≤ 5 × ULN.
- Participant has recovered to Grade 1 toxicity from prior cancer therapy (a participant with Grade 2 neuropathy or Grade 2 alopecia is an exception to this criterion and may qualify for this study).
- Female participant of childbearing potential is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug.
- Male participant agrees to use an adequate method of contraception and not donate sperm starting with the first dose of study drug through 90 days after the last dose of study drug.
- (For Stage 3): CNS inclusion
- Based on screening brain magnetic resonance imaging indicating no evidence of brain metastasis or needing immediate local therapy.
- Participant is able to eat a high fat meal.
- Participant is able to fast for a minimum of 10 hours before start of visit and for an additional 4 hours after study visit. Extension Phase:
- ECOG performance status of 0 to 2.
- Adequate organ function as defined: Absolute neutrophil count ≥ 1,500/μL (For Stage 3: >=1000/μL); Platelets ≥ 100,000/μL; Hemoglobin ≥ 9 g/dL (5.6 mM); serum creatinine ≤ 1.5 × the ULN or a calculated creatinine clearance ≥ 60 mL/min (For Stage 3: ≥ 30 mL/min) using the Cockcroft-Gault equation or 24-hour urine creatinine clearance; Total bilirubin ≤ 1.5 × ULN except in participant with Gilbert’s syndrome. Participants with Gilbert’s syndrome may enroll if direct bilirubin ≤ 1.5 × ULN of the direct bilirubin; AST and ALT ≤ 2.5 × ULN unless liver metastases are present, in which case, they must be ≤5 × ULN
- Female participant of childbearing potential is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug.
- Male participant agrees to use an adequate method of contraception and not donate sperm starting with the first dose of study drug through 90 days after the last dose of study drug.
Exclusion criteria:
- PK Phase:
- Known diagnosis of immunodeficiency
- Symptomatic uncontrolled brain or leptomeningeal metastases.
- Major surgery within 3 weeks of starting the study or participant has not recovered from any effects of any major surgery.
- Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder; nonmalignant systemic disease; or active, uncontrolled infection.
- Known history of myelodysplastic syndrome or acute myeloid leukemia.
- Participant is currently taking any of the following P-glycoprotein (P-gp) inhibitors: amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, ticagrelor, and verapamil (Does not apply for Extension Phase).
- Participant taking proton pump inhibitors, antacids, or histamine 2 blockers within 48 hours prior to study drug administration (Does not apply for Extension Phase).
- Participant has gastric, gastro-esophageal or esophageal cancer; participant is unable to swallow orally administered medication; or participant has gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of niraparib.
- Participant has known active hepatic disease
- Participant has a past or current history of chronic alcohol use.
- Participant has significant pleural effusion or ascites that is expected to require drainage during the PK Phase (Does not apply for Extension Phase).
- For Stage 3 only: Participant is currently taking a lipase inhibitor or cholesterol absorption inhibitor, such as orlistat or ezetimibe, respectively. (Does not apply for participation in Extension Phase of this study).
Trial location(s)
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2022-30-12
Actual study completion date
2023-15-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website